HALIFAX, NS: Immunovaccine, a clinical stage vaccine and immunotherapy companyhas aligned with Incyte – a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology,to evaluate the combination of Immunovaccine's novel T cell activating immunotherapy, DPX-Survivac, with Incyte's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat.
Immunovaccine and Incyteare planning to evaluate the safety, tolerability and efficacy of the novel combination in platinum-sensitive ovarian cancer patients who are at high risk of recurrence. The investigational new drug (IND) application for the study, which will test the triple combination of DPX-Survivac, epacadostat and low dose oral cyclophosphamide, is expected to be filed this year in the U.S. and Canada and the study is expected to enroll approximately 20 patients.
DPX-Survivac and epacadostat both target pathways that have been linked to cancer progression, namely survivin and IDO1. DPX-Survivac is designed to activate T cells of the immune system to recognize survivin-expressing cancer cells. Epacadostat, on the other hand, is designed to inhibit IDO1-mediated immune suppression in the tumor microenvironment. It is therefore hypothesized that co-administration of these immunotherapies may lead to enhanced anti-tumor effects by both activating the immune system to recognize the cancer and simultaneously weakening its defenses.
"DPX-Survivac and epacadostat represent two exciting classes of immune based therapies with promising activity demonstrated in clinical trials."We believe a multi-pronged immune-based treatment approach may be favorable as an alternative to chemotherapy for recurrent ovarian cancer disease," says Marc Mansour, PhD, Chief Executive Officer,Immunovaccine.